Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs.
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
US pharmaceutical company Eli Lilly and Co recently announced a roughly $200 million expansion of its manufacturing site in ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with mirikizumab achieved histologic response at Week 52 ...
Eli Lilly and Company (NYSE:LLY – Get Free Report) shares rose 2.3% on Tuesday . The company traded as high as $920.28 and ...
Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...
The drugmaker Eli Lilly told the-then UK health secretary last year that its new Alzheimer’s drug could be a one-off ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback